Chronic Kidney Disease

Chronic kidney disease (CKD) is the slow, usually silent loss of kidney function over months to years. What makes it so important — and so easy to miss — is that the kidneys can lose more than half their filtering capacity before a patient notices a single symptom. By the time swelling, fatigue, or itching appear, a great deal of irreversible damage may already be done. CKD is now recognised as one of the largest non-communicable disease burdens in the world, quietly driving cardiovascular death, hospitalisation, and the need for dialysis or transplantation.

This page will teach you to think about CKD the way a nephrologist does: not as a single number, but as a two-axis map (how well the kidney filters, and how much protein it leaks), an underlying cause, a set of predictable complications, and — crucially — a disease whose trajectory you can bend with the right interventions.

Learning Objectives

• Define CKD using the KDIGO criteria (structural or functional abnormality for at least 3 months).
• Stage CKD by GFR (G1–G5) and by albuminuria (A1–A3), and explain why both axes matter.
• List the major causes of CKD and identify the two that dominate worldwide.
• Describe the systemic complications of CKD and the mechanisms behind them.
• Apply evidence-based strategies to slow progression, including RAAS blockade and SGLT2 inhibitors.
• Recognise when to refer to nephrology and how CKD interacts with cardiovascular risk.

Quick Answer

CKD is defined as abnormalities of kidney structure or function present for at least 3 months with implications for health. It is staged along two axes: GFR (G1 normal ≥90, down to G5 kidney failure less than 15 mL/min/1.73 m²) and albuminuria (A1 normal, A2 moderately increased, A3 severely increased). The two commonest causes globally are diabetes and hypertension. As GFR falls, patients develop anaemia, mineral-and-bone disorder, acidosis, fluid overload, hyperkalaemia, and — most lethally — accelerated cardiovascular disease. Progression can be slowed by controlling blood pressure, blocking the renin–angiotensin system, using SGLT2 inhibitors, tight glycaemic control, and avoiding nephrotoxins. Early detection through eGFR and urine albumin-to-creatinine ratio (ACR) is the single most powerful tool we have.

Where It Came From

For most of medical history, kidney disease was recognised only at its end: the syndrome of "dropsy" and "uraemia," where patients swelled, grew drowsy, and died. Richard Bright, working at Guy's Hospital in London in the 1820s and 1830s, made the first great leap by linking dropsy, protein in the urine (which he detected by heating urine over a candle and watching it coagulate), and diseased kidneys found at autopsy. For over a century, chronic kidney disease was simply "Bright's disease."

The modern reframing came much later, and it was driven by a public-health need rather than a single discovery. Through the twentieth century, dialysis and transplantation turned kidney failure from a uniformly fatal condition into a treatable one — but at enormous cost, and only for those who reached specialist care in time. The problem was that patients kept arriving at nephrology clinics already at the brink of dialysis, having been "invisible" for years. Terminology was chaotic: "chronic renal insufficiency," "pre-dialysis," "chronic renal failure" all meant different things to different doctors, making it impossible to study the disease population or compare outcomes.

In 2002 the US National Kidney Foundation's KDOQI initiative published a unifying definition and a five-stage classification based on GFR. This was refined internationally by KDIGO in 2012 into the "heat map" that adds albuminuria as a second axis. The motivation throughout was epidemiological: to make CKD countable, comparable, and catchable early. Once you could measure it in the whole population using two cheap tests — a blood creatinine (converted to eGFR) and a urine ACR — CKD could finally be recognised for what it is: a common, progressive, and largely preventable public-health problem affecting roughly one in ten adults.

Defining and Staging CKD

CKD is diagnosed when either a marker of kidney damage or a reduced GFR persists for at least 3 months. The 3-month rule is what separates chronic disease from acute kidney injury, which may fully reverse. Markers of damage include albuminuria (ACR ≥30 mg/g), urine sediment abnormalities, electrolyte disturbances from tubular disorders, structural abnormalities on imaging (e.g., polycystic kidneys), or a history of transplantation.

The GFR axis (G1–G5)

GFR — the volume of plasma filtered per minute — is the best overall index of kidney function. In practice we estimate it (eGFR) from serum creatinine, age, and sex using equations such as CKD-EPI.

Stage	eGFR (mL/min/1.73 m²)	Description
G1	90 or above	Normal or high (damage present)
G2	60–89	Mildly decreased
G3a	45–59	Mild to moderate
G3b	30–44	Moderate to severe
G4	15–29	Severely decreased
G5	less than 15	Kidney failure

A key subtlety: G1 and G2 are not CKD on the GFR number alone. A person with eGFR 95 is normal unless they also have a marker of damage such as albuminuria. This prevents over-labelling healthy older people whose eGFR naturally drifts down.

The albuminuria axis (A1–A3)

Albuminuria reflects both glomerular injury and systemic endothelial/vascular damage, which is why it independently predicts progression and cardiovascular death.

Category	ACR (mg/g)	Term
A1	less than 30	Normal to mildly increased
A2	30–300	Moderately increased
A3	greater than 300	Severely increased

The KDIGO "heat map" combines the two axes into a risk grid running from green (low risk) through yellow and orange to red (very high risk). A patient with G3a A1 is very different from one with G3a A3 — same filtration, but the second has far higher risk and needs more aggressive treatment.

Worked example: A 62-year-old man with type 2 diabetes has a serum creatinine giving eGFR 52 mL/min/1.73 m², and a urine ACR of 180 mg/g, both confirmed on repeat 4 months apart. He is staged as CKD G3a A2. On the heat map this falls in the "high risk" (orange) zone — he needs a RAAS blocker, an SGLT2 inhibitor, blood-pressure and glucose targets, and nephrology co-management.

Causes: Following the Damage Upstream

Worldwide, two causes dominate:

1. Diabetic kidney disease — the single largest cause. Chronic hyperglycaemia damages the glomerular filtration barrier, initially causing hyperfiltration and albuminuria, then progressive scarring (glomerulosclerosis).
2. Hypertensive nephrosclerosis — sustained high pressure damages the small renal arterioles and glomeruli.

Other important causes include glomerulonephritis (immune-mediated glomerular inflammation, e.g., IgA nephropathy), polycystic kidney disease (the commonest inherited cause), chronic obstruction (stones, prostatic enlargement, tumours), reflux nephropathy, chronic use of nephrotoxins (NSAIDs, some herbal remedies, long-term calcineurin inhibitors), and recurrent pyelonephritis. In many low-income regions, CKD of unknown aetiology (linked to heat stress and agricultural labour) is a growing concern.

A practical clinical habit: whenever you find reduced eGFR, ask "diabetes? blood pressure? obstruction? drugs? family history? blood or protein in the urine?" — this five-question sweep catches most reversible or treatable contributors.

Complications: Why the Whole Body Suffers

As nephron mass falls, the kidney's endocrine and homeostatic jobs fail in a predictable sequence:

• Anaemia — reduced erythropoietin production (plus iron deficiency and shortened red-cell survival) causes a normocytic anaemia, typically emerging around G3b–G4.
• CKD–Mineral and Bone Disorder (CKD-MBD) — failing kidneys cannot excrete phosphate or activate vitamin D. Phosphate rises, calcium falls, and secondary hyperparathyroidism develops, weakening bone and calcifying vessels. This is a major driver of cardiovascular death.
• Metabolic acidosis — the kidney cannot excrete the daily acid load; low bicarbonate worsens bone disease, muscle wasting, and progression itself.
• Hyperkalaemia — reduced potassium excretion, often worsened by the very RAAS blockers used to protect the kidney; can be life-threatening.
• Fluid overload and hypertension — sodium and water retention drive oedema, pulmonary congestion, and rising blood pressure, which in turn accelerates kidney damage.
• Cardiovascular disease — the dominant cause of death in CKD. Most patients with CKD die of heart disease before ever reaching dialysis. Uraemic toxins, inflammation, vascular calcification, and volume overload all contribute.
• Uraemic syndrome (G5) — nausea, anorexia, pruritus, pericarditis, encephalopathy, and bleeding tendency, signalling the need for kidney replacement therapy.

Slowing Progression: Bending the Curve

The central message of modern nephrology is that CKD progression is modifiable. Key levers:

1. Blood-pressure control — target generally around 120–130 mmHg systolic (individualised), reducing the mechanical and neurohormonal stress on glomeruli.
2. RAAS blockade — an ACE inhibitor or ARB reduces intraglomerular pressure and albuminuria, especially valuable in diabetic and proteinuric CKD. Expect a small early rise in creatinine (up to ~25–30%) and monitor potassium; a stable modest rise is acceptable and reflects the drug working.
3. SGLT2 inhibitors — a genuine breakthrough. Drugs such as dapagliflozin and empagliflozin slow progression and reduce cardiovascular and kidney events in both diabetic and non-diabetic CKD, by reducing hyperfiltration.
4. Glycaemic control in diabetes, with newer agents (GLP-1 receptor agonists, and the non-steroidal MRA finerenone for diabetic CKD with albuminuria) adding protection.
5. Reduce albuminuria — it is both a marker and a target; lowering it correlates with slower decline.
6. Lifestyle and avoidance — stop smoking, restrict dietary sodium, moderate protein intake, treat obesity, and avoid nephrotoxins (especially NSAIDs and contrast where possible).
7. Treat the complications — correcting acidosis with bicarbonate and managing CKD-MBD may themselves slow decline.

Referral to nephrology is warranted for eGFR less than 30, ACR greater than 300, rapid decline, refractory hypertension or hyperkalaemia, suspected genetic or glomerular disease, or unclear cause.

Real-World Applications

In primary care, CKD detection is largely a matter of routine annual screening of at-risk patients (diabetes, hypertension, cardiovascular disease, family history) with eGFR and urine ACR — two inexpensive tests that identify disease years before symptoms. On hospital wards, recognising a patient's CKD stage changes drug dosing (many drugs need adjustment or are contraindicated in low GFR), guides contrast and NSAID avoidance, and flags the risk of acute-on-chronic kidney injury during illness or surgery. In everyday life, the same principles that protect the kidney — controlling blood pressure and blood sugar, not overusing painkillers, staying hydrated, not smoking — are the ones patients can act on themselves.

Common Mistakes

• Misconception: "Normal creatinine means normal kidneys." Serum creatinine is insensitive early and depends on muscle mass; an elderly, low-muscle patient can have a "normal" creatinine with a substantially reduced eGFR. Correction: use eGFR and check albuminuria, not creatinine alone.
• Misconception: "A rise in creatinine after starting an ACE inhibitor means the drug is harming the kidney and must be stopped." A modest, stable rise (up to ~25–30%) is expected and reflects reduced intraglomerular pressure — the protective mechanism. Correction: only stop for a large rise (suggesting renal artery stenosis or volume depletion) or dangerous hyperkalaemia; otherwise continue and monitor.
• Misconception: "CKD patients mostly die of kidney failure/on dialysis." In fact most, especially in earlier stages, die of cardiovascular disease first. Correction: treat CKD as a cardiovascular risk state, aggressively managing BP, lipids, and using kidney-protective agents.

Comparison and Connections

Feature	Acute Kidney Injury (AKI)	Chronic Kidney Disease (CKD)
Timeframe	Hours to days	3 months or more
Reversibility	Often reversible	Largely irreversible
Kidney size (imaging)	Usually normal	Often small, shrunken
Anaemia / CKD-MBD	Usually absent	Common in later stages
Baseline function	Previously normal	Persistently abnormal

Note that AKI and CKD interact: AKI accelerates future CKD, and CKD predisposes to AKI ("acute-on-chronic"). CKD staging (GFR + albuminuria) also connects directly to cardiovascular risk stratification — the albuminuria axis is as much a vascular marker as a renal one.

Practice Questions

Recall

Q: What two axes are used to stage CKD under KDIGO, and what is the minimum duration required for diagnosis? A: GFR category (G1–G5) and albuminuria category (A1–A3), with abnormalities persisting for at least 3 months.

Understanding

Q: Why does albuminuria predict cardiovascular events and not just kidney progression? A: Albumin leak reflects generalised endothelial and vascular dysfunction, not only glomerular injury; it therefore marks systemic vascular disease, which drives cardiovascular events alongside kidney decline.

Application

Q: A patient has eGFR 40 and ACR 500 mg/g on two occasions 3 months apart. Stage the CKD and name two drug classes that slow progression. A: CKD G3b A3 (very high risk). Progression-slowing options include an ACE inhibitor or ARB (RAAS blockade) and an SGLT2 inhibitor; finerenone is a further option in diabetic CKD with albuminuria.

Analysis

Q: A diabetic patient's creatinine rises 20% one week after starting an ACE inhibitor, with normal potassium. What is happening and what should you do? A: The expected haemodynamic effect of reduced intraglomerular pressure — a beneficial, protective change. Continue the drug, recheck creatinine and potassium, and do not stop unless the rise exceeds ~25–30% or hyperkalaemia develops (which would raise suspicion of renal artery stenosis or volume depletion).

FAQ

Is CKD reversible? Generally no — established scarring does not heal. But progression can be dramatically slowed, and treating reversible contributors (obstruction, nephrotoxins, dehydration) can improve function. Early-stage CKD may remain stable for decades.

Does everyone with CKD end up on dialysis? No. Most people with early CKD never reach dialysis; many die of cardiovascular disease first, and many others remain stable. Only a minority progress to G5 requiring kidney replacement therapy.

Why do my kidneys affect my blood count and my bones? The kidney is an endocrine organ: it makes erythropoietin (needed for red-cell production) and activates vitamin D (needed for calcium and bone health), and it excretes phosphate. When kidney function falls, anaemia and mineral-bone disorder follow.

Should CKD patients avoid all protein and potassium? Not indiscriminately. Modest protein moderation may help, and potassium is restricted only when levels are high. Overly restrictive diets risk malnutrition — dietary changes should be individualised, ideally with a renal dietitian.

Are SGLT2 inhibitors only for diabetics? No. Landmark trials showed they slow progression and reduce cardiovascular and kidney events in CKD patients with and without diabetes, which is why they are now core kidney-protective therapy.

Quick Revision

• CKD = kidney damage or eGFR less than 60 for at least 3 months.
• Staged by GFR (G1–G5) and albuminuria (A1–A3) — the KDIGO heat map.
• G1/G2 need a damage marker (e.g., albuminuria) to count as CKD.
• Top two causes worldwide: diabetes and hypertension.
• Complications: anaemia, CKD-MBD, acidosis, hyperkalaemia, fluid overload, cardiovascular disease.
• Cardiovascular disease is the leading cause of death in CKD.
• Slow progression: BP control, RAAS blockade, SGLT2 inhibitors, glycaemic control, avoid nephrotoxins.
• A modest creatinine rise after starting an ACE inhibitor/ARB is expected and acceptable.
• Refer to nephrology if eGFR less than 30, ACR greater than 300, or rapid decline.

Related Topics

Prerequisites

• Nephrology overview
• Renal physiology and the glomerular filtration barrier (see ../../2._Physiology/index.md)

Related Topics

• Diabetes and its complications (see ../../27._Endocrinology/index.md)
• Cardiovascular disease and hypertension (see ../../25._Cardiology/index.md)

Next Topics

• Acute Kidney Injury
• Dialysis and kidney replacement therapy
• Glomerular diseases